OmniAb, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Matthew W. Foehr
- Full Time Employees
- 114
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5980 Horton Street EmeryVille CA United States of America 94608
- IPO Date
- Sep 30, 2021
- CIK
- 0001846253
- Website
- omniab.com
- Similar Companies
- Business
- OmniAb, Inc. (OABI) is a biotechnology company that licenses proprietary transgenic animal platforms and discovery technologies to pharmaceutical, biotechnology and academic partners worldwide to enable the discovery of next-generation antibody-based therapeutics. The company offers a suite of genetically engineered animals including OmniRat, OmniChicken, OmniMouse, OmniFlic, OmniClic and OmniTaur for generating fully human or humanized antibodies; OmnidAb for single-domain antibodies; high-throughput single B-cell screening via the xPloration platform; and OmniDeep computational tools leveraging AI and machine learning for antibody optimization, with applications spanning bispecific biologics, antibody-drug conjugates, CAR-T therapies, radiotherapeutics and ion channel/transporter targets. Founded in 2012 and headquartered in Emeryville, California, OmniAb operates globally with over 100 active partners, 95 of which support 378-399 programs including 32-33 in clinical development or commercialization as of early 2025. Recent developments include the May 2025 launch of the xPloration Partner Access Program allowing partners to purchase the screening instrument for in-house use; a research collaboration and license with Orion Corporation for an ion-channel target offering over $55 million in milestones; an asset sale to Angelini Pharma for a Kv7.2 program with $3 million upfront and over $170 million potential milestones; a co-discovery alliance with VERAXA Biotech for bispecific antibody-drug conjugates; a November 2025 technology license and services agreement with Mabtrx Biosciences using OmnidAb technology for equity, services revenue and royalties; and an August 2025 $30 million private placement to bolster liquidity and corporate purposes.
OmniAb Q1 Earnings Call Highlights
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
OmniAb to Participate in Three Upcoming Investor Conferences
OmniAb to Report First Quarter 2026 Financial Results on May 7
Matthew Foehr Sells 19,244 Shares of OmniAb (NASDAQ:OABI) Stock
OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript
OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates
OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
OmniAb (OABI) Projected to Post Earnings on Wednesday
OmniAb to Report Fourth Quarter 2025 Financial Results on March 4
OmniAb, Inc. (OABI) Discusses Launch and Scientific Overview of OmniUltra Technology Platform Transcript
Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies
OmniAb to Hold OmniUltra Virtual Investor Event on December 15
OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors
OmniAb, Inc. (OABI) Q3 2025 Earnings Call Transcript
OmniAb, Inc. (OABI) Reports Q3 Loss, Misses Revenue Estimates
OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights
OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy?
OmniAb to Participate in Three Investor Conferences in November